Ligand director sells 4,591 shares in open market

LIGAND PHARMACEUTICALS INC director John L. Lamattina reported selling 4,591 shares of Common Stock on June 10, 2026 in a series of open-market transactions.

Rhea-AI Filing Summary

LIGAND PHARMACEUTICALS INC director John L. Lamattina reported selling 4,591 shares of Common Stock on June 10, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $246.63 to $251.90 per share across the different trades.

Individual transactions included sales such as 3,405 shares at a weighted-average price of $251.6158 and smaller blocks at prices around $247–$250 per share. Following these sales, he directly holds 26,969 shares of Ligand Pharmaceuticals Common Stock.

Insider Trade Summary

Net Seller: 4,591 shares

Net Sell 4 txns

Insider LAMATTINA JOHN L

Role Director

Sold 4,591 shs ($1.15M)

Type	Security	Shares	Price	Value
Sale	Common Stock	257	$247.2237	$64K
Sale	Common Stock	232	$248.1111	$58K
Sale	Common Stock	697	$249.5326	$174K
Sale	Common Stock	3,405	$251.6158	$857K

Holdings After Transaction: Common Stock — 26,969 shares (Direct)

Footnotes (4)

1. F1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 4,591 shares Sale block at $251.6158: 3,405 shares at $251.6158/share Price range footnote F1: $246.63–$247.61 per share +2 more

5 metrics

Shares sold 4,591 shares Total Common Stock sold on June 10, 2026

Sale block at $251.6158 3,405 shares at $251.6158/share Open-market sale on June 10, 2026

Price range footnote F1 $246.63–$247.61 per share Multiple transactions underlying a weighted-average sale price

Price range footnote F4 $250.91–$251.895 per share Multiple transactions underlying a weighted-average sale price

Shares owned after transaction 26,969 shares Direct Common Stock ownership following a June 10, 2026 sale

Key Terms

open-market sale, weighted-average price, Common Stock, Form 4

4 terms

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LGND director John L. Lamattina report?

John L. Lamattina reported selling 4,591 shares of Ligand Pharmaceuticals (LGND) Common Stock. The sales occurred on June 10, 2026 in multiple open-market transactions at weighted-average prices around the high-$240s to low-$250s per share.

How many LGND shares did John L. Lamattina sell and at what prices?

He sold a total of 4,591 LGND Common Stock shares. Weighted-average prices for the four sale blocks were approximately $247.22, $248.11, $249.53, and $251.62 per share, reflecting multiple trades within narrow intraday price ranges.

On what date did the LGND insider sales by John L. Lamattina occur?

All reported sales by John L. Lamattina occurred on June 10, 2026. The Form 4 details four separate open-market sale transactions in Ligand Pharmaceuticals (LGND) Common Stock executed that day at different weighted-average price points.

How many LGND shares does John L. Lamattina own after the reported sales?

After the reported sales, John L. Lamattina directly holds 26,969 shares of Ligand Pharmaceuticals (LGND) Common Stock. This post-transaction holding figure is shown in the Form 4 as the number of shares owned following one of the June 10, 2026 transactions.

Were John L. Lamattina’s LGND sales open-market transactions?

Yes. Each transaction in the Form 4 is coded “S” and described as an open-market or private sale. The filing specifies that prices are weighted averages for multiple trades within stated ranges for each block of Ligand Pharmaceuticals (LGND) shares sold.

What do the weighted-average prices in the LGND Form 4 footnotes mean?

Weighted-average prices mean each reported price reflects many trades at slightly different prices. For LGND, the footnotes state shares were sold in multiple transactions within specific ranges, and detailed trade-level pricing is available to investors upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:26 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAMATTINA JOHN L

(Last) (First) (Middle)

555 HERITAGE DRIVE

SUITE 200

(Street)

JUPITER FLORIDA 33458

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		S		257	D	$247.2237(1)	31,303	D
Common Stock	06/10/2026		S		232	D	$248.1111(2)	31,071	D
Common Stock	06/10/2026		S		697	D	$249.5326(3)	30,374	D
Common Stock	06/10/2026		S		3,405	D	$251.6158(4)	26,969	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $246.6300 to $247.6100. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $247.9400 to $248.3350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $249.3400 to $250.2700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $250.9100 to $251.8950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	By: /s/ Andrew Reardon, Attorney-in-Fact For: John L. LaMattina	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)